

Meagan Myers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/193356/publications.pdf>

Version: 2024-02-01

18
papers

342
citations

933447

10
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

630
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Fixation and Spread of Somatic Mutations in Adult Human Colonic Epithelium. <i>Cell Stem Cell</i> , 2018, 22, 909-918.e8. | 11.1 | 89 |
| 2 | Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas. <i>Neoplasia</i> , 2016, 18, 253-263. | 5.3 | 37 |
| 3 | ACBâ€PCR measurement of Hâ€ras codon 61 CAAâ€™CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues. <i>Environmental and Molecular Mutagenesis</i> , 2012, 53, 495-504. | 2.2 | 22 |
| 4 | Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide. <i>Toxicological Sciences</i> , 2013, 136, 26-38. | 3.1 | 22 |
| 5 | A subset of papillary thyroid carcinomas contain <i>KRAS</i> mutant subpopulations at levels above normal thyroid. <i>Molecular Carcinogenesis</i> , 2014, 53, 159-167. | 2.7 | 22 |
| 6 | Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, 9, 7. | 0.7 | 20 |
| 7 | <i>KRAS</i> mutant tumor subpopulations can subvert durable responses to personalized cancer treatments. <i>Personalized Medicine</i> , 2013, 10, 191-199. | 1.5 | 19 |
| 8 | Low-frequency <i>KRAS</i> mutations are prevalent in lung adenocarcinomas. <i>Personalized Medicine</i> , 2015, 12, 83-98. | 1.5 | 19 |
| 9 | Variation in organâ€™specific <i>PIK3CA</i> and <i>KRAS</i> mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas. <i>Environmental and Molecular Mutagenesis</i> , 2017, 58, 466-476. | 2.2 | 16 |
| 10 | Hotspot oncomutations: implications for personalized cancer treatment. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 603-620. | 3.1 | 13 |
| 11 | Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk. <i>Environmental and Molecular Mutagenesis</i> , 2020, 61, 152-175. | 2.2 | 13 |
| 12 | Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids. <i>PLoS ONE</i> , 2020, 15, e0238862. | 2.5 | 12 |
| 13 | Ovarian effects of prenatal exposure to benzo[a]pyrene: Roles of embryonic and maternal glutathione status. <i>Reproductive Toxicology</i> , 2017, 69, 187-195. | 2.9 | 10 |
| 14 | Dose and temporal evaluation of ethylene oxideâ€™induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations. <i>Environmental and Molecular Mutagenesis</i> , 2017, 58, 122-134. | 2.2 | 10 |
| 15 | Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1011. | 4.1 | 8 |
| 16 | Quantification of cancer driver mutations in human breast and lung <sc>DNA</sc> using targeted, errorâ€™corrected <sc>CarcSeq</sc>. <i>Environmental and Molecular Mutagenesis</i> , 2020, 61, 872-889. | 2.2 | 6 |
| 17 | CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia. <i>Toxicological Sciences</i> , 2021, 182, 142-158. | 3.1 | 3 |
| 18 | Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia. <i>Toxicological Sciences</i> , 2021, 184, 1-14. | 3.1 | 1 |